Tokai plans for Phase III trial of galeterone in 2015

Tokai Pharmaceuticals — a US-based biotechnology company — went public yesterday and was supposedly able to raise more than enough money to initiate a pivotal, Phase III, randomized clinical trial of its investigational drug galeterone (TOK-001) in treatment of late stage prostate cancer. … READ MORE …

Projecting urinary and sexual function after first-line treatment for prostate cancer

Data from a study conducted by a research team at Fox Chase Cancer Center here in Philadelphia may be able, in time, to help to identify when and how much various prostate cancer treatments will impact urinary and sexual functioning. … READ MORE …

Is the “flare” response to initiation of LHRH therapy “real” or not?

For all of the past 30 years, it has been the accepted wisdom that starting a patient on medically induced androgen deprivation therapy (ADT, e.g., with leuproplide acetate/Lupron) during treatment of prostate cancer placed the patient at risk for an initial “flare” response that induced a short-term stimulus to serum testosterone levels and therefore to the development of any tumor. … READ MORE …

Bayer, Orion initiate Phase III trial of ODM-201 in non-metastatic CRPC

According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to  enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …

Baldness patterns, genetics, and risk for prostate cancer

According to a newly-published study in the Journal of Clinical Oncology, certain types of male baldness are associated with a heightened risk for aggressive forms of prostate cancer (but this finding really needs to be confirmed in other studies). … READ MORE …

D’Amico on the individualization of prostate cancer risk management

In an interesting article in the September 2014 issue of The ASCO Post, Dr. Anthony D’Amico argues in favor of a future in which individualized approaches to risk will replace PSA screening alone as a means of determining who actually needs to be biopsied and (if necessary) receive treatment for clinically significant prostate cancer. … READ MORE …

Cancer screening re-visited again

An article by Melinda Beck in today’s issue of The Wall Street Journal discusses the complex topic of screening, “over-diagnosis”, and over-treatment of low-risk forms of certain cancers (prostate cancer specifically included). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers